Pluristem Therapeutics (NASDAQ: PSTI) and Bio-Path Holdings (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Analyst Recommendations

This is a summary of current ratings for Pluristem Therapeutics and Bio-Path Holdings, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluristem Therapeutics 0 0 3 0 3.00
Bio-Path Holdings 0 0 2 0 3.00

Pluristem Therapeutics presently has a consensus target price of $3.83, suggesting a potential upside of 227.64%. Bio-Path Holdings has a consensus target price of $3.50, suggesting a potential upside of 1,043.79%. Given Bio-Path Holdings’ higher probable upside, analysts clearly believe Bio-Path Holdings is more favorable than Pluristem Therapeutics.

Insider and Institutional Ownership

4.5% of Pluristem Therapeutics shares are held by institutional investors. Comparatively, 15.2% of Bio-Path Holdings shares are held by institutional investors. 7.0% of Pluristem Therapeutics shares are held by company insiders. Comparatively, 12.5% of Bio-Path Holdings shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Pluristem Therapeutics and Bio-Path Holdings’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Pluristem Therapeutics N/A N/A -$25.40 million ($0.33) -3.55
Bio-Path Holdings $13,000.00 2,355.16 -$8.69 million ($0.07) -4.37

Bio-Path Holdings has higher revenue and earnings than Pluristem Therapeutics. Bio-Path Holdings is trading at a lower price-to-earnings ratio than Pluristem Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Pluristem Therapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, Bio-Path Holdings has a beta of 3.04, meaning that its share price is 204% more volatile than the S&P 500.


This table compares Pluristem Therapeutics and Bio-Path Holdings’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pluristem Therapeutics N/A -81.96% -66.69%
Bio-Path Holdings N/A -56.53% -43.24%


Bio-Path Holdings beats Pluristem Therapeutics on 9 of the 10 factors compared between the two stocks.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.

About Bio-Path Holdings

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with's FREE daily email newsletter.